BTEK.L vs. BRK-B

Last updated Apr 2, 2026

Compare and contrast key facts about iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and Berkshire Hathaway Inc. (BRK-B).

BTEK.L is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Oct 19, 2017.

Performance

BTEK.L vs. BRK-B - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and Berkshire Hathaway Inc. (BRK-B). The values are adjusted to include any dividend payments, if applicable.

BTEK.L vs. BRK-B - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF	4.66%	23.81%	-0.32%	0.33%	-1.55%	0.90%	23.11%	21.63%	-6.34%	-3.31%
BRK-B Berkshire Hathaway Inc.	-3.23%	2.99%	29.31%	9.69%	15.59%	30.17%	-0.64%	6.71%	9.11%	1.48%

Different Trading Currencies

BTEK.L is traded in GBP, while BRK-B is traded in USD. To make them comparable, the BRK-B values have been converted to GBP using the latest available exchange rates.

Returns By Period

In the year-to-date period, BTEK.L achieves a 4.66% return, which is significantly higher than BRK-B's -3.23% return.

BTEK.L

• 1D: 1.49%
• 1M: -0.54%
• YTD: 4.66%
• 6M: 18.91%
• 1Y: 35.66%
• 3Y*: 10.55%
• 5Y*: 5.47%
• 10Y*: —

BRK-B

• 1D: -0.38%
• 1M: 0.78%
• YTD: -3.23%
• 6M: -2.33%
• 1Y: -12.48%
• 3Y*: 12.98%
• 5Y*: 14.10%
• 10Y*: 13.58%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BTEK.L vs. BRK-B — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BTEK.L

BTEK.L Risk / Return Rank: 84
BTEK.L Sharpe Ratio Rank: 82
BTEK.L Sortino Ratio Rank: 82
BTEK.L Omega Ratio Rank: 75
BTEK.L Calmar Ratio Rank: 92
BTEK.L Martin Ratio Rank: 91

BRK-B

BRK-B Risk / Return Rank: 17
BRK-B Sharpe Ratio Rank: 16
BRK-B Sortino Ratio Rank: 16
BRK-B Omega Ratio Rank: 16
BRK-B Calmar Ratio Rank: 17
BRK-B Martin Ratio Rank: 19

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BTEK.L vs. BRK-B - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BTEK.L	BRK-B	Difference
Sharpe ratio Return per unit of total volatility	1.65	-0.66	+2.31
Sortino ratio Return per unit of downside risk	2.24	-0.80	+3.04
Omega ratio Gain probability vs. loss probability	1.29	0.90	+0.40
Calmar ratio Return relative to maximum drawdown	3.52	-0.73	+4.25
Martin ratio Return relative to average drawdown	13.00	-1.11	+14.12
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BTEK.L vs. BRK-B - Sharpe Ratio Comparison

The current BTEK.L Sharpe Ratio is 1.65, which is higher than the BRK-B Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of BTEK.L and BRK-B, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BTEK.L	BRK-B	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.65	-0.66	+2.31
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.27	0.84	-0.56
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.69	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.31	0.58	-0.27

Correlation

The correlation between BTEK.L and BRK-B is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BTEK.L vs. BRK-B - Dividend Comparison

Neither BTEK.L nor BRK-B has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BTEK.L vs. BRK-B - Drawdown Comparison

The maximum BTEK.L drawdown since its inception was -30.86%, smaller than the maximum BRK-B drawdown of -37.92%. Use the drawdown chart below to compare losses from any high point for BTEK.L and BRK-B.

Drawdown Indicators

	BTEK.L	BRK-B	Difference
Max Drawdown Largest peak-to-trough decline	-30.86%	-53.86%	+23.00%
Max Drawdown (1Y) Largest decline over 1 year	-12.96%	-14.95%	+1.99%
Max Drawdown (5Y) Largest decline over 5 years	-30.86%	-26.58%	-4.28%
Max Drawdown (10Y) Largest decline over 10 years	—	-29.57%	—
Current Drawdown Current decline from peak	-1.07%	-11.36%	+10.29%
Average Drawdown Average peak-to-trough decline	-10.18%	-11.07%	+0.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.86%	8.72%	-5.86%

Volatility

BTEK.L vs. BRK-B - Volatility Comparison

iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) has a higher volatility of 6.98% compared to Berkshire Hathaway Inc. (BRK-B) at 4.68%. This indicates that BTEK.L's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BTEK.L	BRK-B	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.98%	4.68%	+2.30%
Volatility (6M) Calculated over the trailing 6-month period	13.75%	12.29%	+1.46%
Volatility (1Y) Calculated over the trailing 1-year period	21.52%	18.95%	+2.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	20.15%	16.95%	+3.20%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	21.71%	19.84%	+1.87%